Data as of Jan 30
| -1.61 / -3.93%|
The 2 analysts offering 12-month price forecasts for Biospecifics Technologies Corp have a median target of 50.50, with a high estimate of 55.00 and a low estimate of 46.00. The median estimate represents a +28.37% increase from the last price of 39.34.
The current consensus among 2 polled investment analysts is to Buy stock in Biospecifics Technologies Corp. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.